J&J feels the heat as DES intensifies
This article was originally published in Clinica
Executive Summary
Despite challenges in the drug-eluting stent (DES) sector such as increased competition and the continued weakness in the US market, Johnson & Johnson's medical device and diagnostics arm reported a 7.2% growth in sales during the first quarter of 2008.